Microbiome innovation for animal health.
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health.
Microbiome innovation for animal health.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
20% of farm animal productivity is lost to disease
We need new tools to keep animals healthy in a sustainable and environmentally responsible way.
Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of the microbiome.
Meet the BiomEdit team
The BiomEdit team is a diverse and balanced mix of both experienced executives and new talent. This includes 20 PhD scientists occupying positions in Discovery, Development, Analytics, Regulatory, and Marketing. Collectively, the team has over 200 peer-reviewed publications and almost 50 patents, and 30% of us have experience taking a new product to market.
Our platform is based on samples of microbial populations collected from a large number of animals.
These samples represent what the microbiome looks like in healthy, diseased, and dysbiotic states. These populations are then characterized at the genomic, transcriptomic, and metabolomic levels to generate a microbial atlas for each animal species: a comprehensive dataset describing what bacteria are present, how abundant they are, and what functions they perform within that ecosystem.
Microbial atlases provide us with a wealth of resources to draw from and allow us to identify novel candidate probiotic species with unique functions and properties. Rather than being limited to the chance discovery of a bacterial strain with beneficial effects, we are able to selectively identify strains with desired characteristics. We also use a similar approach to the discovery of bioactive microbial metabolites and peptides. In some applications, new probiotic species are then engineered to produce proteins that can direct the immune response, similarly to a vaccine or an anti-toxin.
Our discovery platform generates three different types of products: probiotics, bioactive compounds, and engineered microbial medicines.
Probiotics
At first glance, our strains are similar to traditional probiotics. The key difference is that ours have been selected from our microbial atlases to perform a specific function more efficiently and effectively than thousands of other strains. Each probiotic is fully characterized and sequenced, so we have complete confidence in what it is and how it will perform.
Bioactives
Sometimes, the beneficial effect of a bacterial strain is due to one or two compounds that it produces. In these cases, it’s more cost effective and efficient to administer the purified compound to the animal. These products can range from metabolites that influence how bacteria communicate with each other to proteins that affect the intestinal immune system.
Engineered microbial medicines
One of the most challenging parts of developing health solutions can be delivering the right compound where and when it’s needed most. Probiotics that colonize and persist in the gut offer a unique platform to deliver proteins and peptides directly into the gastrointestinal system. We have a targeted selection of probiotic strains optimized as delivery systems for different species and conditions.
Recent publications from our team
Aquaculture is in need of sustainable solutions to promote health and performance, especially in high-value species. This paper highlights BiomEdit’s unique approach to developing novel products for salmon and the potential impact of this research
Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis.
Growth promotion and antibiotic induced metabolic shifts in the chicken gut microbiome.
Multi-Omics Characterization of Host-Derived Bacillus spp. Probiotics for Improved Growth Performance in Poultry.
Our investors and supporters
Microbiome innovation for animal health
